Medical Cannabis for Children with ADHD in the UK: What Parents Need to Know

Introduction

Medical cannabis for children with ADHD is one of the most sensitive and carefully regulated areas of UK prescribing. While adult ADHD patients have seen growing access to cannabis-based medicinal products (CBMPs) since legalisation in 2018, paediatric prescribing operates under substantially stricter rules. This guide is intended for parents who have heard about medical cannabis as a potential option and want an honest, evidence-based overview of what is and is not possible in the UK.

The Legal and Regulatory Framework

Under UK law, medical cannabis can be prescribed to children, but only by a specialist clinician — typically a paediatric neurologist or paediatric psychiatrist — and only in exceptional circumstances where all other treatment options have been exhausted. The prescribing clinician must be a consultant-level specialist and must take full clinical responsibility for the prescription.

For paediatric ADHD specifically, the bar is extremely high. The NHS does not routinely fund or endorse medical cannabis for children with ADHD, and the number of private specialists willing to prescribe in this context is very small. Most UK medical cannabis clinics that operate in the adult space do not offer paediatric services.

What Does the Evidence Say?

The clinical evidence for medical cannabis in paediatric ADHD is limited and largely observational. There are no large-scale randomised controlled trials in children with ADHD. The available data comes primarily from:

• Case reports and small case series — mostly from Israel and the United States, where medical cannabis access for children is more established in certain states

• Parent-reported outcomes — several surveys of parents of children with ADHD who have used cannabis products report improvements in hyperactivity, impulsivity, and sleep, but these are subject to significant placebo and reporting bias

• Observational data from the UK Medical Cannabis Registry (UKMCR) — the UKMCR includes a small number of paediatric patients, but ADHD-specific paediatric data has not yet been published in peer-reviewed form

A 2019 study published in Scientific Reports examined 53 children with ADHD treated with cannabis oil in Israel. After six months, 30 of the 53 patients were assessed: 14 showed significant improvement, 8 showed moderate improvement, and 8 showed no change. Side effects included sleep disturbance, decreased appetite, and restlessness in a minority of patients.

It is important to be clear: this evidence is not sufficient to recommend medical cannabis as a treatment for paediatric ADHD. The NHS and NICE do not endorse it, and the risks — including potential effects on the developing brain — are not yet fully understood.

The Developing Brain: A Critical Consideration

The human brain continues to develop until approximately age 25. THC, the psychoactive component of cannabis, is known to interact with the endocannabinoid system in ways that may affect neurodevelopment. Animal studies have shown that early-life THC exposure can alter dopamine signalling, affect memory formation, and increase vulnerability to anxiety disorders in adulthood.

For this reason, paediatric prescribing in the UK — where it occurs at all — typically involves CBD-dominant or CBD-only products, with THC avoided or minimised. The risk-benefit calculation is fundamentally different for a child than for an adult.

When Might Paediatric Prescribing Be Considered?

In the UK, paediatric medical cannabis prescribing for ADHD is most likely to be considered in the following narrow circumstances:

• The child has a confirmed ADHD diagnosis from a paediatric specialist

• Multiple conventional ADHD medications (methylphenidate, lisdexamfetamine, atomoxetine, guanfacine) have been tried and have failed or caused intolerable side effects

• The prescribing clinician is a paediatric specialist with experience in cannabinoid medicine

• The family has been fully counselled on the limited evidence base and potential risks

• There is a clear clinical rationale documented in the patient record

How CPGUK Can Help

CPGUK does not recommend or facilitate medical cannabis prescriptions for children with ADHD outside of the formal specialist pathway described above. However, we can help parents:

• Understand whether their child might meet the eligibility criteria for a specialist referral

• Identify the small number of UK paediatric specialists who have experience with CBMPs

• Navigate the process of obtaining a referral from their GP or existing paediatrician

• Access the most up-to-date clinical guidance and research

If you are a parent exploring this option, please contact CPGUK for free, confidential guidance. We will always give you an honest assessment of what is realistically possible.

Conclusion

Medical cannabis for children with ADHD in the UK is legally possible but practically rare, clinically cautious, and subject to strict specialist oversight. The evidence base is limited, the risks to the developing brain are real, and the number of clinicians willing to prescribe in this context is small. Parents should approach this area with careful research and realistic expectations — and CPGUK is here to help with that process.